A peripheral marker for schizophrenia: Increased levels of D ₃ dopamine receptor mRNA in blood lymphocytes

Abstract

Dopamine is a major neurotransmitter in the central nervous system, and its receptors are associated with a number of neuropathological disorders such as Parkinson's disease and schizophrenia. Although the precise pathophysiology of schizophrenia remains unknown, the dopaminergic hypothesis of the illness assumes that the illness results from excessive activity at dopamine synapses in the brain. Because, at present, the diagnosis of schizophrenia relies on descriptive behavioral and symptomatic information, a peripheral measurable marker may enable a simpler, more rapid, and more accurate diagnosis and monitoring. In recent years, human peripheral blood lymphocytes have been found to express several dopamine receptors (D3, D4, and D5) by using molecular biology techniques and binding assays. It has been suggested that these dopamine receptors found on lymphocytes may reflect receptors found in the brain. Here we demonstrate a correlation between the D3 dopamine receptor on lymphocytes and schizophrenia and show a significant elevation of at least 2-fold in the mRNA level of the D3, but not of the D4, dopamine receptor in schizophrenic patients. This increase is not affected by different antipsychotic drug treatments (typical or atypical). Moreover, nonmedicated patients exhibit the same pattern, indicating that this change is not a result of medical treatment. We propose the D 3 receptor mRNA on blood lymphocytes as a marker for identification and followup of schizophrenia. S chizophrenia is a neuropsychiatric disorder afflicting about one percent of the population. Although its exact pathogenesis is still not known precisely, a common belief is that excessive activity at dopaminergic synapses in the brain plays a prominent role (1). To date, a definitive diagnosis of schizophrenia requires a 6-month duration of symptomatology and relies on heterogeneous symptoms. Because there is neither an effective biological marker for identifying schizophrenia (2, 3), nor an accurate and rapid diagnosis to ensure more optimal management at an early stage in the illness (4), there remains a vital need for a convenient assay for diagnosis and followup of schizophrenia.Most of the drugs used to treat schizophrenia act to control symptoms by neuroreceptor antagonism. Moreover, the dopaminergic basis of schizophrenia is strongly supported by the close correlation between clinical efficacy of antipsychotic medications and their potency to antagonize the binding of dopamine to its receptors (5).Dopamine receptors are divided into two subclasses, D1 and D2. The D1 subclass contains the D 1 and D 5 receptor subtypes, and the D2 subclass contains the D 2 , D 3 , and D 4 subtypes (6). The dopamine hypothesis of schizophrenia specifically relates to the D2 subclass. Notably, most drugs effective in treating schizophrenia exhibit D2 receptor antagonistic activity, and administration of a selective D1-like antagonist has been reported to result in the worsening of symptoms (7). The D 3 receptor, one among the three in the D2 subclass, is...

Dopamine D1-Like Receptor Antagonist Attenuates Th17-Mediated Immune Response and Ovalbumin Antigen-Induced Neutrophilic Airway Inflammation

“…The extent of dopamine receptor expression is different among diseases (51)(52)(53)(54)(55). For example, expression of D3 receptor is upregulated in schizophrenia (51,52).…”

“…For example, expression of D3 receptor is upregulated in schizophrenia (51,52). Expression of D2-like-R decreased in Alzheimer's disease (53).…”

Dopamine, through the Extracellular Signal-Regulated Kinase Pathway, Downregulates CD4+CD25+Regulatory T-Cell Activity: Implications for Neurodegeneration

“…Previous studies have documented the effect of dopamine on T-cell adhesion (Levite et al, 2001), on activation (Ilani et al, 2001), and on T-lymphocyte suppression of IgG production by peripheral blood mononuclear cells (Kirtland et al, 1980). No attempt was made in any of those studies to attribute the dopamine effect to subpopulations of CD4 ϩ T-cells.…”

Multifunctional Pharmacotherapy: What Can We Learn from Study of Selective Serotonin Reuptake Inhibitor Augmentation of Antipsychotics in Negative-Symptom Schizophrenia?

“…Peripheral mononuclear cells may reflect molecular processes in the CNS of schizophrenic patients and have been used to study various substances including cytokines (e.g., interleukins IL-6, IL-10, and IL-2), receptors for major neurotransmitters (e.g., dopamine, serotonin, and GABA A ), and G-protein subunits that regulate intracellular signal transduction. [53][54][55][56][57][58][59][60][61] Chertkow et al 62 used microarrays to examine the gene expression profile of peripheral mononuclear cells in schizophrenia patients on steady antipsychotic treatment before and 3 and 6 weeks after addition of fluvoxamine and found changes in transcripts related to Gprotein coupled receptors. Using customized cDNA array and real-time RT-PCR, they also found significant downregulation of chemokine receptors IL8RA and CCR1, and of RGS7 mRNA.…”